Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
NCT ID: NCT07203287
Last Updated: 2025-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
490 participants
INTERVENTIONAL
2025-08-26
2027-08-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
"The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery
NCT06521307
Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis
NCT02618317
High-Dose N-Acetylcysteine in Cardiac Surgery
NCT00332631
An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
NCT00122018
N-Acetylcysteine for Preventing Renal Injury After Cardiac Surgery
NCT00188630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Both of which are current standard of care practices. Appropriate reversal will be performed and documented, and the patient will go to the recovery room or intensive care unit as planned preoperatively. The patients will be assessed postoperatively for up to 7 days for any signs of respiratory complications, including but not limited to:
1. Atelectesis
2. Hypoxia
3. Respiratory distress/failure
4. Pneumonia
5. Pneumothrax
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rocuronium and Sugammadex (RS) Group
The participants will be given rocuronium and sugammadex as part of one of the standard regimens of neuromuscular blockade and reversal.
Rocuronium
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Sugammadex
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Cisatracurium and Neostigmine (CN) Group
The participants will be given cisatracurium and neostigmine as part of one of the standard regimens of neuromuscular blockade and reversal.
Cisatracurium
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Neostigmine
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rocuronium
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Cisatracurium
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Sugammadex
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Neostigmine
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject must be between 18 and 80 years of age
* The subject should have chronic kidney disease as defined by glomerular filtration rate
* The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade
Exclusion Criteria
* Any patient over the age of 80
* Any patient with end stage renal disease
* Any patient requiring dialysis
* Patients presenting for Renal Transplantation
* Pregnant Female
* Any patient in the correctional system
* Urgent or Emergent procedure
* The surgery requires intubation post-operatively
* Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas Medical Branch, Galveston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Arango, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Medical Branch
Galveston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-0406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.